Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Theralase Technologies (TSE:TLT)
:TLT
Holding TSE:TLT?
Track your performance easily
Earnings Data
Report Date
Apr 23, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
―Last Year’s EPS
―Same Quarter Last Year
Based on 0 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 29, 2018
|% Change Since: -6.67%
|Next Earnings Date:Jul 26, 2018
Earnings Call Sentiment|Neutral
The earnings call reflects a cautiously optimistic outlook, with significant progress in clinical trials and a strategic plan for future growth. However, financial challenges due to decreased revenue and increased selling expenses pose concerns. The company's ability to raise funds and reduce net loss are positive indicators, balancing the setbacks.Company Guidance
During the Theralase Technologies Inc's quarterly investor conference call, key financial metrics for the third quarter of the fiscal year 2024 were discussed, including a 12% year-over-year decrease in total revenue to CAD622,984 and a gross margin decline to 47% due to increased material costs. The company reported a net loss of CAD3,337,995, a 7% improvement from the previous year, largely due to reduced research and development spending. The drug division accounted for 84% of this loss, focusing heavily on the Phase II bladder cancer clinical study, which showed promising results with a 61.9% complete response rate. The company also raised approximately CAD3.93 million through private placements and plans to secure further funding to complete the bladder cancer study, estimated to cost between CAD15 million and CAD30 million over the next three years. Additionally, Theralase is exploring the commercialization phase, aiming for regulatory approval by the end of 2026, with plans to expand into treating brain, lung, and blood cancers.Phase II Bladder Cancer Clinical Study Success
96% of 75 patients treated have been evaluated at the 90-day assessment with a 61.9% complete response rate. Including indeterminate responses, the total response rate is 68.3%, showing significant efficacy in treating BCG-unresponsive non-muscle invasive bladder cancer.
Reduced Net Loss
Net loss reduced by 7% year-over-year to CAD3,337,995, primarily due to decreased spending on research and development expenses in Study II.
Successful Capital Raising
Raised gross proceeds of approximately CAD3,930,500 through five non-brokered private placements.
Strong Safety Profile
100% of patients experienced no serious adverse events directly related to the study drug or study device.
Strategic Expansion Plans
Plans to add five new clinical study sites and increase enrollment to complete Study II enrollment in 2025.
---
TSE:TLT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
TSE:TLT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 27, 2024 | C$0.30 | C$0.21 | -30.00% |
| Aug 12, 2024 | C$0.20 | C$0.18 | -10.00% |
| May 30, 2024 | C$0.15 | C$0.14 | -6.67% |
| Mar 27, 2024 | C$0.18 | C$0.16 | -11.11% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Theralase Technologies (TSE:TLT) report earnings?
Theralase Technologies (TSE:TLT) is schdueled to report earning on Apr 23, 2025, TBA Not Confirmed.
What is Theralase Technologies (TSE:TLT) earnings time?
Theralase Technologies (TSE:TLT) earnings time is at Apr 23, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TSE:TLT EPS forecast?
Currently, no data Available
---